Fortress Biotech, Inc. (NASDAQ:FBIO) tinted gains of +1.68% (+0.06 points) to US$3.64. The volume of 0.11 Million shares climbed down over an trading activity of 166.38 Million shares. EPS ratio determined by looking at last 12 month figures is -0.68. Over the same time span, the stock marked US$5.54 as its best level and the lowest price reached was US$3.14. The corporation has a market cap of US$199.62 Million.
Fortress Biotech, Inc. (NASDAQ:FBIO)’s earnings per share has been growing at a 14.2 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -149.3 percent while most common profitability ratio return on investment (ROI) was -51.2 percent. The company’s institutional ownership is monitored at 13.2 percent. The company’s net profit margin has achieved the current level of -40.5 percent and possesses 98 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 0 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 2. 3 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Argan, Inc. (NYSE:AGX) is worth US$621.34 Million and has recently risen 1.67% to US$39.5. The latest exchange of 0.24 Million shares is below its average trading activity of 235.24 Million shares. The day began at US$38.85 but the price moved to US$38.67 at one point during the trading and finally capitulating to a session high of US$39.25. The stock tapped a 52-week high of US$70.7 while the mean 12-month price target for the shares is US$49.33.
Currently, the stock carries a price to earnings ratio of 8.75, a price to book ratio of 1.72, and a price to sales ratio of 0.7. For the past 5 years, the company’s revenue has grown 26.2%, while the company’s earnings per share has grown 22.3%. With an institutional ownership near 85.7%, it carries an earnings per share ratio of 4.51.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 0 brokerage firms polled by Factset Research. At present, 2 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 1 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.67.